Microbot Medical Appoints Seasoned Endovascular Sales Executive to Lead its U.S. Sales Activities for LIBERTY® Endovascular Robotic System

Core Insights - Microbot Medical Inc. has appointed Paul Mullen as Vice President of Sales, marking the company's first commercial hire as it prepares for FDA clearance anticipated in Q2 2025 [1][3] Company Overview - Microbot Medical Inc. is a pre-commercial stage medical technology company focused on developing the LIBERTY Endovascular Robotic System, which aims to redefine endovascular robotics and improve patient care globally [4] Appointment Details - Paul Mullen brings extensive experience in the endovascular medical device market, having previously served as Director of Sales at Inari Medical, which was acquired by Stryker Corporation for $4.94 billion [2] - Mullen's responsibilities will include building the sales strategy and infrastructure for a successful product launch following FDA clearance [1][3] Market Context - The endovascular space is critical for treating conditions such as deep vein thrombosis and pulmonary embolisms, with Mullen having successfully launched multiple innovative devices in this area [2] - The company aims to eliminate barriers to access for advanced robotic technologies in the endovascular field, potentially benefiting millions of patients [4]